This study is testing if artesunate vaginal inserts can help treat cervical intraepithelial neoplasia (CIN2/3), which are pre-cancerous changes in the cervix often caused by HPV (human papillomavirus) infection. You might be able to join if you are a woman aged 25 or older with a confirmed diagnosis of CIN2 or CIN3 and any type of HPV. The study aims to see how many participants show improvement in their cervical tissue by week 17. Participants will receive either artesunate vaginal inserts or a placebo (an inactive substance) for three cycles. The study is currently unclear on its recruitment status and plans to enroll 78 participants.

Study design

This is a phase II, double-blind study, meaning neither you nor your doctor will know if you are receiving artesunate or placebo. Participants are randomly assigned in a 2:1 ratio to receive either artesunate or placebo vaginal inserts.

What's involved

You would receive three 5-day cycles of vaginal inserts at weeks 0, 2, and 4. Dosing visits can be done via telehealth, with medication mailed to your home. You will have follow-up visits at weeks 6, 17, and 40, and all participants will undergo a LEEP procedure (a common treatment for CIN) at week 17.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed after receiving artesunate at weeks 6, 17, and 40.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.